Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 80
- Registration Number
- NCT02302495
- Locations
- 🇫🇷
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
🇫🇷Hopital J Monod, Montivilliers, France
🇫🇷Centre Hospitalier de la côte basque, Bayonne, France
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02294357
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Blood & Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Mehrdad Abedi, MD
- Target Recruit Count
- 10
- Registration Number
- NCT02293109
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02269085
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT02265510
- Locations
- 🇺🇸
Site 2, Nashville, Tennessee, United States
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 22
- Registration Number
- NCT02257476
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1
- Registration Number
- NCT02235740
- Locations
- 🇺🇸
Novartis Investigative Site, Cary, North Carolina, United States
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Mario Boccadoro
- Target Recruit Count
- 477
- Registration Number
- NCT02203643
- Locations
- 🇮🇹
IRCCS--CROB --CROB di Rionero in di Rionero in Vulture, Rionero in Vulture, Italy
Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 36
- Registration Number
- NCT02204241
- Locations
- 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.